within Pharmacolibrary.Drugs.ATC.C;

model C10BX17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10BX17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rosuvastatin and ramipril are used in combination therapy for cardiovascular risk reduction; rosuvastatin is a statin used to lower cholesterol and ramipril is an ACE inhibitor used for hypertension and heart failure. The fixed combination is approved in some countries for patients requiring both treatments.</p><h4>Pharmacokinetics</h4><p>No published population pharmacokinetic studies or dedicated PK study specific for the fixed-dose combination C10BX17. Estimates are based on the known oral pharmacokinetics of rosuvastatin and ramipril individually in healthy adults.</p><h4>References</h4><ol><li><p>Ferri, N, &amp; Corsini, A (2025). [Clinical pharmacology of combination therapies for the prevention and treatment of cardiovascular diseases]. <i>Giornale italiano di cardiologia (2006)</i> 26(1 Suppl 2) e6–e16. DOI:<a href=&quot;https://doi.org/10.1714/4425.44225&quot;>10.1714/4425.44225</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39898749/&quot;>https://pubmed.ncbi.nlm.nih.gov/39898749</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10BX17;
